In last trading session, Lyra Therapeutics Inc (NASDAQ:LYRA) saw 1.96 million shares changing hands with its beta currently measuring 0.04. Company’s recent per share price level of $0.12 trading at $0.0 or -2.91% at ring of the bell on the day assigns it a market valuation of $7.68M. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.82 million shares which gives us an average trading volume of 1.01 million if we extend that period to 3-months.
For Lyra Therapeutics Inc (LYRA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Upright in the red during last session for losing -2.91%, in the last five days LYRA remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $0.12 price level, adding 25.0% to its value on the day. Lyra Therapeutics Inc’s shares saw a change of -43.51% in year-to-date performance and have moved -25.21% in past 5-day. Lyra Therapeutics Inc (NASDAQ:LYRA) showed a performance of -35.93% in past 30-days. Number of shares sold short was 2.4 million shares which calculate 2.53 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 0.5 to the stock, which implies a rise of 76.0% to its current value. Analysts have been projecting 0.5 as a low price target for the stock while placing it at a high target of 0.5. It follows that stock’s current price would drop -316.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -316.67% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.22% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 42.42% while estimates for its earnings growth in next 5 years are of 21.95%.
Lyra Therapeutics Inc (NASDAQ:LYRA)’s Major holders
Insiders are in possession of 0.42% of company’s total shares while institution are holding 50.86 percent of that, with stock having share float percentage of 51.07%. Investors also watch the number of corporate investors in a company very closely, which is 50.86% institutions for Lyra Therapeutics Inc that are currently holding shares of the company. PERCEPTIVE ADVISORS LLC is the top institutional holder at LYRA for having 12.76 million shares of worth $3.53 million. And as of 2024-06-30, it was holding 19.4892 of the company’s outstanding shares.
The second largest institutional holder is CITADEL ADVISORS LLC, which was holding about 4.77 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.2912 of outstanding shares, having a total worth of $1.32 million.
